Results of the SEL-I-METRY phase II trial on resensitization of advanced iodine refractory differentiated thyroid cancer to radioiodine therapy
Name:
Thyroid-2023.Wadsley.Ainsworth.pdf
Size:
153.8Kb
Format:
PDF
Description:
Found with Open Access Button
Authors
Wadsley, JAinsworth, G
Coulson, AB
Garcez, Kate
Moss, L
Newbold, K
Farnell, K
Swain, J
Howard, H
Beasley, M
Weaver, A
Wood, K
Marshall, J
Griffin, M
Pascoe, A
Du, Y
Taprogge, J
Flux, G
Brown, S
Affiliation
Christie NHS Foundation Trust, Manchester, United KingdomIssue Date
2023
Metadata
Show full item recordCitation
Wadsley J, Ainsworth G, Coulson AB, Garcez K, Moss L, Newbold K, et al. Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy. Thyroid : official journal of the American Thyroid Association. 2023 SEP 1;33(9):1119-23. PubMed PMID: WOS:001068436200011. English.Journal
ThyroidDOI
10.1089/thy.2022.0707PubMed ID
37565288Additional Links
https://dx.doi.org/10.1089/thy.2022.0707Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1089/thy.2022.0707
Scopus Count
Collections
Related articles
- Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial.
- Authors: Brown SR, Hall A, Buckley HL, Flanagan L, Gonzalez de Castro D, Farnell K, Moss L, Gregory R, Newbold K, Du Y, Flux G, Wadsley J
- Issue date: 2019 Jun 14
- Advances in the molecular mechanism and targeted therapy of radioactive-iodine refractory differentiated thyroid cancer.
- Authors: Zhang L, Li Z, Zhang M, Zou H, Bai Y, Liu Y, Lv J, Lv L, Liu P, Deng Z, Liu C
- Issue date: 2023 Jul 31
- Radioiodine Refractory Differentiated Thyroid Cancer.
- Authors: Chan WWL, Chan S, Kwong DLW
- Issue date: 2022
- Target therapies for radioiodine refractory advanced thyroid tumors.
- Authors: Schlumberger M
- Issue date: 2012